Denmark · Biotechnology startup
Denmark · Hemab
Hemab is a clinical-stage biotech company developing prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.
Funding reportedLast round: Series B
Follow Hemab and see its new rounds in your feed.Start following
What company datasets say Hemab raised
Funding, as reported
Reported in all190Min the source's currency
Rounds3
Last roundSeries B
Last round dateFeb 2023
Investors listed9
Founders and team
From Hemab's own website: 15 on the team.
- Angela VolkertVice President, Clinical Research
- Erik BjornsonVice President, Regulatory Affairs
- Karen WeisbachChief People and Culture Officer
- Eva BøgeSenior Director, Regulatory Affairs
- Jennifer DupeeExecutive Assistant/Office Manager
- Keli WalbertDirector
- Leyna ChoSenior Clinical Trial Associate
- Louise Almsgaard HeltSenior Finance Business Partner
- Maj Invest EquitySenior Finance Business Partner
- Matthew BandelSenior Clinical Trial Associate
- Michelle FisherDirector, Data Management
- Per JeppesenDirector, CMC Drug Product Development
- Shea GoldenSenior Clinical Trial Associate
- Shivangi MathyAssociate Director, Clinical Operations
- Tara ParsonsAssociate Director, Clinical Operations
On 3 portfolio pages
Investors who name them
Each firm lists Hemab on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Denmark
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Hemab in front of investors. Or tell us what we have wrong.